RNA Interference (RNAi) has emerged as a breakthrough in the life sciences industry. It presents extensive potential in multiple areas, such as drug discovery, drug development, and therapeutic applications for various indications along with aiding in the basic research. It has been found that, various components, such as siRNA & miRNA possess immense opportunities and provides a wide range in different drug classes. Besides, these molecules find wide applications in various sectors, such as functional genomics, disease diagnostics, and agriculture, among others. Many studies indicate that the usage of siRNA and miRNA in industries and academic institutions will witness a substantial growth with the passage of time.
According to new research reports and analysis, the global RNAi market is anticipated to grow stupendously at a CAGR of around 28% during 2010 - 2015. Incessant growth of the industry will be mainly driven by the rising utilization of this expertise as a research gizmo in functional genomics, which is used in drug discovery, target validation, and drug development along with agricultural & plant biotechnology sectors. It is believed that, the RNAi market will also be driven by the advancement of RNAi-based therapeutics for multiple indications in future.
At the segment level, Nanoparticle RNAi delivery holds the maximum share in the global market. However, share of RNAi delivery through Nucleic Acid & Aptamer will experience substantial growth in the coming years.
Companies are flourishing by synthesizing dsRNAs and pools for RNAs, providing vectors, transfection reagents, transfection apparatus, and enzymes for creating dsRNAs that do not require synthetic RNAs. Further, RNAi gene silencing has attracted a large amount of investment; perhaps more than since the advent of PCR or gene sequencing.
Completed and On-going Clinical Testing Programs for RNAi Therapeutics